Smith+Nephew (NYSE: SNN) today announced plans for a months-long roadshow across Central Europe to promote its Cori surgical ...

Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report ... To highlight a few, CORI, EVOS, REGENETEN and our Negative Pressure Wound Therapy portfolio, all delivered strong double ...

Key platforms, such as CORI , EVOS , REGENETEN and our Negative Pressure Wound Therapy portfolio all delivered strong double-digit growth in the quarter, and we are maintaining our high ...

Smith+Nephew (NYSE ... Plan driving growth across our portfolio,” said Smith+Nephew CEO Deepak Nath. “Key platforms, such as Cori, Evos, Regeneten and our Negative Pressure Wound Therapy ...

LONDON (dpa-AFX) - Global medical technology company Smith+Nephew (SNN, SN.L), on Wednesday, reported steady revenue growth in the first quarter of 2025 despite various market challenges.

Smith & Nephew reported its first-quarter 2025 earnings, showcasing a revenue of $1.4 billion, with underlying growth at 3.1%, surpassing its guidance. The company faced a 1.2% reported growth due to ...

Smith & Nephew reported its first-quarter 2025 earnings, showcasing a revenue of $1.4 billion, with underlying growth at 3.1%, surpassing its guidance. The company faced a 1.2% reported growth due ...

(Alliance News) - Smith & Nephew PLC shares climbed on Wednesday as it said it made a good start to 2025 as revenue increased. The Watford, England-based medical technology company said first ...

"While unhelpful, recent China setbacks seem temporary and Smith+Nephew is slowly reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts," Jefferies analysts ...